Warner drug factory: subsidiary passes on-site inspection by US FDA.

On March 15, Warner Pharmaceutical Factory announced that its wholly-owned subsidiary, Hunan Warner Dachemical Co., Ltd., received a pre-approval inspection from the U.S. Food and Drug Administration for chiral drugs from November 10th to November 14th, 2025. Recently, the company received a on-site inspection report issued by the U.S. FDA forwarded by the chiral drug company. The report indicated that the FDA confirmed that the inspection had concluded, and the chiral drug company passed the on-site inspection, demonstrating that the pantoprazole sodium API production line of the chiral drug company complies with the requirements of the U.S. FDA in terms of production management quality system, regulatory compliance, etc., which will have a positive impact on the company's future business performance and enhance its international market competitiveness.